(Q34555308)

3 August 2017

title

Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas (English)

1 reference

3 August 2017

main subject

phase I clinical trial

0 references

author name string

R I Jakacki

1

1 reference

3 August 2017

E Dombi

2

1 reference

3 August 2017

D M Potter

3

1 reference

3 August 2017

S Goldman

4

1 reference

3 August 2017

J C Allen

5

1 reference

3 August 2017

I F Pollack

6

1 reference

3 August 2017

B C Widemann

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

3 August 2017

1 reference

3 August 2017

volume

76

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

265-272

1 reference

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Plexiform neurofibromas in NF1: toward biologic-based therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

A prospective 10 year follow up study of patients with neurofibromatosis type 1

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

The role of interferon alfa in the treatment of metastatic melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Neurofibromatosis type 1--an update and review for the primary pediatrician

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

The interferon system. A bird's eye view of its biochemistry

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Peginterferon alfa-2a in patients with chronic hepatitis C.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034394

Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference

27 October 2018

1 reference

12 December 2020

Peripheral nerve sheath tumors. Histogenesis, classification, and prognosis

1 reference

12 December 2020

Interferon-alpha for neurofibromas

1 reference

12 December 2020

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas

1 reference

12 December 2020

10.1212/WNL.0B013E318207B031

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference